Tus Pharmaceutical Group Co Ltd Total Liabilities
Tus Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Tus Pharmaceutical Group Co Ltd (000590) has total liabilities worth CN¥333.17 Million CNY (≈ $48.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 000590 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tus Pharmaceutical Group Co Ltd (1995–2025)
Total liabilities of Tus Pharmaceutical Group Co Ltd from 1995 to 2025. This chart illustrates how Tus Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 000590 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tus Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tus Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hedef Holdings AS
IS:HEDEF
|
Turkey | TL1.10 Billion |
|
Imperial Brands PLC
LSE:IMB
|
UK | GBX23.62 Billion |
|
Leonteq AG
SW:LEON
|
Switzerland | CHF10.47 Billion |
|
Rapac Communication & Infrastructure Ltd
TA:RPAC
|
Israel | ILA1.07 Billion |
|
Pengana Private Equity Trust
AU:PE1
|
Australia | AU$15.18 Million |
|
Aurion Resources Ltd
V:AU
|
Canada | CA$5.95 Million |
|
Sampo Corp
TW:1604
|
Taiwan | NT$11.04 Billion |
|
Instone Real Estate Group AG
XETRA:INS
|
Germany | €1.17 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Tus Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 000590 asset base.
Liquidity & Leverage Metrics
Tus Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Tus Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tus Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tus Pharmaceutical Group Co Ltd (1995–2025)
The table below shows the annual total liabilities of Tus Pharmaceutical Group Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥339.98 Million ≈ $49.75 Million |
-17.52% |
| 2024-12-31 | CN¥412.18 Million ≈ $60.32 Million |
-2.54% |
| 2023-12-31 | CN¥422.92 Million ≈ $61.89 Million |
-8.90% |
| 2022-12-31 | CN¥464.26 Million ≈ $67.94 Million |
+62.61% |
| 2021-12-31 | CN¥285.50 Million ≈ $41.78 Million |
+15.46% |
| 2020-12-31 | CN¥247.27 Million ≈ $36.18 Million |
+10.10% |
| 2019-12-31 | CN¥224.58 Million ≈ $32.86 Million |
-5.19% |
| 2018-12-31 | CN¥236.88 Million ≈ $34.66 Million |
-18.43% |
| 2017-12-31 | CN¥290.40 Million ≈ $42.50 Million |
-20.81% |
| 2016-12-31 | CN¥366.72 Million ≈ $53.66 Million |
-3.91% |
| 2015-12-31 | CN¥381.64 Million ≈ $55.85 Million |
-5.23% |
| 2014-12-31 | CN¥402.71 Million ≈ $58.93 Million |
+42.28% |
| 2013-12-31 | CN¥283.05 Million ≈ $41.42 Million |
+25.56% |
| 2012-12-31 | CN¥225.44 Million ≈ $32.99 Million |
-10.41% |
| 2011-12-31 | CN¥251.62 Million ≈ $36.82 Million |
-13.19% |
| 2010-12-31 | CN¥289.85 Million ≈ $42.41 Million |
+1.66% |
| 2009-12-31 | CN¥285.11 Million ≈ $41.72 Million |
+14.72% |
| 2008-12-31 | CN¥248.53 Million ≈ $36.37 Million |
+2.97% |
| 2007-12-31 | CN¥241.37 Million ≈ $35.32 Million |
-11.94% |
| 2006-12-31 | CN¥274.10 Million ≈ $40.11 Million |
-30.79% |
| 2005-12-31 | CN¥396.04 Million ≈ $57.95 Million |
-3.18% |
| 2004-12-31 | CN¥409.06 Million ≈ $59.86 Million |
-3.98% |
| 2003-12-31 | CN¥426.00 Million ≈ $62.34 Million |
-4.04% |
| 2002-12-31 | CN¥443.96 Million ≈ $64.96 Million |
+6.62% |
| 2001-12-31 | CN¥416.40 Million ≈ $60.93 Million |
+62.51% |
| 2000-12-31 | CN¥256.24 Million ≈ $37.50 Million |
+2.88% |
| 1999-12-31 | CN¥249.06 Million ≈ $36.45 Million |
+83.72% |
| 1998-12-31 | CN¥135.56 Million ≈ $19.84 Million |
+2.52% |
| 1997-12-31 | CN¥132.23 Million ≈ $19.35 Million |
+190.34% |
| 1996-12-31 | CN¥45.54 Million ≈ $6.66 Million |
-39.87% |
| 1995-12-31 | CN¥75.74 Million ≈ $11.08 Million |
-- |
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offer… Read more